Global Uterine Fibroid Embolization Devices Market, By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques), Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment) – Industry Trends and Forecast to 2029.
Global Uterine Fibroid Embolization Devices Market Analysis and Size
In recent years, Uterine fibroid embolization (UFE) have been highly deployed globally due to its minimally invasive technique. The technique incorporates the use of a real-time x-ray called fluoroscopy to guide the delivery of embolic agents to the uterus and fibroids. About 90% of women who have undergone UFE experience significant or complete resolution of their fibroid-related symptoms.
- Global Uterine Fibroid Embolization Devices Market was valued at USD 5.01 billion in 2021 and is expected to reach USD 7.08 billion by 2029, registering a CAGR of 4.40% during the forecast period of 2022-2029. “The minimally invasive treatment” accounts for the largest mode of treatment segment in the respective market owing to the high awareness regarding the technique among people.
Global Uterine Fibroid Embolization Devices Market Definition
Uterine fibroid embolization (UFE) refers to a minimally invasive treatment that is widely utilized for treating fibroid tumors in the uterus. The procedure is referred as a uterine artery embolization (UAE), and is used for treating other complications such as placenta previa, arteriovenous malformations of the pelvis and placenta accrete.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques), Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Boston Scientific Corporation (US), Merit Medical Systems (US), BioSpace (US), Hologic, Inc. (US), Cook (UK), Ferring B.V. (Switzerland), Smith+Nephew (UK), CooperSurgical, Inc. (US), Aetna Better Health of Pennsylvania (US), Ethicon US, LLC (US), Olympus America (US), Stryker (US), among others
|
|
Market Opportunities
|
|
Uterine Fibroid Embolization Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Prevalence of Uterine Fibroids
The rise in the prevalence of uterine fibroids among women across the acts as one of the major factors driving the growth of uterine fibroid embolization devices market.
- Preference for Minimally Invasive Surgery
The increase in the preference for minimally invasive surgery owing to the advantages, such as smaller incisions decrease post-operative pain and speedy recovery, accelerate the market growth.
- Increase in Funds
The surge in funding from private and government organizations for development of healthcare sector and research centers further influence the market.
Opportunities
Furthermore, advancements in the procedure and devices devices extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, rise in healthcare awareness among the patients will further expand the market.
Restraints/Challenges Global Uterine Fibroid Embolization Devices Market
On the other hand, high cost of medical devices and ongoing healthcare reforms are expected to obstruct market growth. Also, stringent regulations are projected to challenge the uterine fibroid embolization devices market in the forecast period of 2022-2029.
This uterine fibroid embolization devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on uterine fibroid embolization devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Uterine Fibroid Embolization Devices Market
COVID-19 had a negative impact on the uterine fibroid embolization devices market owing to the decline in elective surgeries. Hospital access was restricted to non-essential care, and O&P clinics were temporarily closed during the pandemic. The implementation of social distancing, lockdown of the population and limited access to clinics greatly affected the market. The slow-down in patient flow and referrals, and decline in trauma and workplace injuries also impacted the market growth. However, market will resume its growth in the post-pandemic due to the easing in restrictions that were imposed earlier.
Recent Development
- Karl Storz has launched Tele Pack+, a compact endoscopy system in March’2020. The system is a transportable video system that assists in merging all of the key components, such as light source, display and camera control unit together required for diagnosis and treatment.
- Gynesonics, developed Sonata System in July’2020. The system is transcervical fibroid ablation system that makes use of radiofrequency energy for treating symptomatic uterine fibroids. The system detects and then target a single fibroid with a combination of radiofrequency and ultrasound.
Global Uterine Fibroid Embolization Devices Market Scope and Market Size
The uterine fibroid embolization devices market is segmented on the basis of technology and mode of treatment. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- Surgical Techniques
- Laparoscopic Techniques
- Ablation Techniques
- Embolization Techniques
Based on technology, uterine fibroid embolization devices market is segmented into surgical techniques, laparoscopic techniques, ablation techniques and embolization techniques. Surgical techniques have been further segmented into hysterectomy and myomectomy. Laparoscopic Techniques have been further segmented into laparoscopic myomectomy and myolysis. Ablation Techniques have been further segmented into microwave ablation, hydrothermal ablation, cryoablation, ultrasound ablation and other ablation techniques. Ultrasound ablation is segmented into high-intensity focused ultrasound (HIFU) and MRI-guided focused ultrasound (MRGFUS).
Mode of Treatment
- Invasive Treatment
- Minimally Invasive Treatment
- Non-Invasive Treatment
Uterine fibroid embolization devices market has also been segmented based on the mode of treatment into invasive treatment, minimally invasive treatment and non-invasive treatment.
Uterine Fibroid Embolization Devices Market Regional Analysis/Insights
The uterine fibroid embolization devices market is analysed and market size insights and trends are provided by country, technology and mode of treatment as referenced above.
The countries covered in the uterine fibroid embolization devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the uterine fibroid embolization devices market because of the presence of well-established healthcare facilities within the region.
Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the large patient base and unmet needs regarding the fibroids diagnosis and treatment in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The uterine fibroid embolization devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for uterine fibroid embolization devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the uterine fibroid embolization devices market. The data is available for historic period 2010-2020.
Competitive Landscape and Uterine Fibroid Embolization Devices Market Share Analysis
The uterine fibroid embolization devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to uterine fibroid embolization devices market.
Some of the major players operating in the uterine fibroid embolization devices market are
- Boston Scientific Corporation (US)
- Merit Medical Systems (US)
- BioSpace (US)
- Hologic, Inc. (US)
- Cook (UK)
- Ferring B.V. (Switzerland)
- Smith+Nephew (UK)
- CooperSurgical, Inc. (US)
- Aetna Better Health of Pennsylvania (US)
- Ethicon US, LLC (US)
- Olympus America (US)
- Stryker (US)
Research Methodology : Global Uterine Fibroid Embolization Devices Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-uterine-fibroid-embolization-devices-market
SKU-